You may not log in without verifying your email address.
Please check your email (including your spam email) for the Welcome message that was sent.
Nilotinib-d3 is a labeled analogue of Nilotinib which functions as a Bcr-Abl tyrosine kinase antagonist. Studies suggest that Nilotinib-d3 inhibits proliferation, migration and actin filament formation in HSCs. In addition, Nilotinib-d3 can cause apoptosis in HSCs via reducing the expression of bcl-2 and increasing the expression p53, cleavage of PARP, along with an increased expression of PPARγ and TRAIL-R. Nilotinib-d3 strongly inhibits the phosphorylation of ERK and Akt1 via suppressing PDGF and TGFβ. Alternatively, Nilotinib-d3 shows significant efficacy towards chronic myeloid leukemia in chronic, accelerated, and blastic phases. Nilotinib-d3 is far more effective than imatinib (sc-267106) and dasatinib (sc-358114) at inhibiting rhodamine 123 and Hoechst 33342 efflux in human hematopoietic stem cells.
1. Dohse, M., et al. 2010. Drug Metab. Dispos. 38: 1371-1380. PMID: 20423956
2. Breccia, M. 2010. Nat Rev Clin Oncol. 7: 557-558. PMID: 20877419
3. Liu, Y., et al. 2011. J Hepatol. [Epub ahead of print]. PMID: 21251937
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.